Back to Market返回行情
99
9926.HK Akeso, Inc.
HKSEHealthcareHK$118.10+6.97%LatestMarket Cap: HK$108.65B
As of 2026-05-29 16:08
Valuation
P/E (TTM)
-84.11
PEG
—
P/B
10.26
P/S
30.96
EV/EBITDA
-101.17
DCF Value
—
FCF Yield
-1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.7%
Operating Margin
-29.6%
Net Margin
-36.4%
ROE
-14.3%
ROA
-6.9%
ROIC
-6.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | HK$1.62B | 78.0% | HK$-481.1M | HK$-533.9M | HK$-0.58 | — |
| Q2 2025 | HK$1.41B | 79.4% | HK$-414.5M | HK$-570.1M | HK$-0.64 | — |
| Q4 2024 | HK$1.10B | 81.6% | HK$-285.8M | HK$-275.9M | HK$-0.32 | — |
| Q2 2024 | HK$1.02B | 91.5% | HK$-272.4M | HK$-238.6M | HK$-0.28 | — |
| Q4 2023 | HK$849.4M | 93.1% | HK$-436.7M | HK$-496.7M | HK$-0.59 | — |
| Q2 2023 | HK$3.68B | 97.9% | HK$2.32B | HK$2.53B | HK$3.01 | — |
| Q4 2022 | HK$674.5M | 88.9% | HK$-790.5M | HK$-538.0M | HK$-0.64 | — |
| Q2 2022 | HK$163.1M | 82.5% | HK$-747.0M | HK$-630.4M | HK$-0.77 | — |
| Q4 2021 | HK$97.0M | 67.4% | HK$-857.8M | HK$-650.0M | HK$-0.80 | — |
| Q2 2021 | HK$128.6M | 98.9% | HK$-506.3M | HK$-424.9M | HK$-0.52 | — |
| Q4 2020 | HK$0.00 | — | HK$-683.3M | HK$-504.3M | HK$-0.64 | — |
| Q2 2020 | HK$0.00 | — | HK$-340.3M | HK$-532.1M | HK$-1.13 | — |